Sanofi-Lilly Settlement Paves Way For Biosimilar Lantus
This article was originally published in Scrip
Executive Summary
A potential launch of Eli Lilly & Co.'s copycat version of Sanofi's blockbuster Lantus (insulin glargine) in 2016 will put pressure on the entire insulin category, including new drugs like Novo Nordisk AS's Tresiba (insulin degludec) and Sanofi's own follow-on Toujeo.
You may also be interested in...
Mylan Scores IPR Victory, Paving The Way For Follow-On Lantus
US Patent and Trademark Office invalidated two patents covering Sanofi's Lantus vial, clearing the way for Mylan to launch a follow-on product after FDA approval.
Mylan Scores IPR Victory, Paving The Way For Follow-On Lantus
US Patent and Trademark Office invalidated two patents covering Sanofi's Lantus vial, clearing the way for Mylan to launch a follow-on product after FDA approval.
The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.